
nolocution

OPE





The Scientific and Technical Information Center (STIC) experienced a problem when processing the following computer readable form (CRF):

Application Serial Number: $\frac{/0/621, 485}{7/16/03}$ Filing Date: $\frac{7/16/03}{28/2003}$ Date Processed by STIC: $\frac{7/28/2003}{2003}$
STIC Contact: Mark Spencer, 703-308-4212
Nature of Problem:
The CRF (was): (circle one) Damaged or Unreadable (for Unreadable, see attached) Blank (no files on CRF) (see attached) Empty file (filename present, but no bytes in file) (see attached) Virus-infected. Virus name: The STIC will not process the CRF. Not saved in ASCII text Sequence Listing was embedded in the file. According to Sequence Rules, submitted file should only be the Sequence Listing. Did not contain a Sequence Listing. (see attached sample) Other:
PLEASE USE THE CHECKER VERSION 4.0 PROGRAM TO REDUCE ERRORS. SEE BELOW FOR ADDRESS: http://www.uspto.gov/web/offices/pac/checker Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom. Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:
1. EFS-Bio (http://www.uspto.gov/ebc/efs/downloads/documents.htm , EFS Submission User Manual - ePAVE)
 U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 Hand Carry directly to: U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202 Or
 U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202 Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
Revised 04/24/2003

10/621485

NO SEQUEST CAN'T MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVAQC 60 QLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKQEEEEMDF RSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKI LKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLS RERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGI 300 KDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFEL 360 ILMEEIRFPRTLGPEAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWQHVYEKK 420 LSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA 480

> This is not a valid Sequence Listing. It is hot in valid Somet. Pleese: 1) consult Sequerce Rules; 2) consult sample Sequence Listing (attached) for VALID Also, Per 1.8240) Sequence Rules, submit only the Sequence Listing submit on computer readable form Do file on computer readable form Do NOT wellede any other ples on the computer readable form.

```
<110>
                Smith, John: Smithgene Inc.
  <120>
                Example of a Sequence Listing
  <130>
               01-00001
                                                                                  <u>اين</u>
               PCT/EP98/00001
 <1(0)
  <1(1)
               1998-12-31
               US 08/999,999
 <150>
 <151>
               1997-10-15
 <160>
 <170>
               PatentIn version 2.0
 <210>
               389
 <211>
 <212>
               ANG
 <213>
               Paramecium sp.
 <220>
 <221>
              CDS
 <222>
              (279) . . . (389)
 <300>
 <301>
              Doc. Richard
              Isolation and Characterization of a Gene Encoding a
 < 302 >
              Protease from Paramecium sp.
<303>
              Journal of Genes
<304>
<305>
              4
              1 - 7
< 306>
< 307 >
              1988-06-31
<308>
              123456
< 309>
              1988-06-31
<400>
                                                                                         60
agelglagic
              altectgtgt*
                           cctcttctct
                                         ctgggcttct
                                                      caccetgeta
                                                                   alcagatete
                                                                                  Œ
                                                                                        120
agggagagtg
             tettgaccet.
                           cctctgcctt
                                         tgcagettea
                                                      caggeaggea
                                                                   ggcaggcagc
tgatgtggca
                                                                                        180
             attigctggca
                                                     aggettaggg
                                                                   tgggttccgc
                           gtgccacagg
                                        cttttcagcc
                                                                                        240
cgcggcgcgg
             cggcccctct
                                                     ctctcgctct
                                                                   cctctcgctc
                           cgcgctcctc
                                        tcgcgcctct
```

...

Consult this

Appendix 3, page 2

```
ato
                                                                 gtt
                                            cagttage
                                                                       tca
                                                                            atg
                                                                                 ttc
                 aggtgagcag
                              0400400000
                                                                                             296
                                                           Het
                                                                 Val
                                                                      Ser
                                                                           Mct
                                                                                 Phc
                                                             1
                   asa tgg cct ggs ttt
Lys Trp Pro Cly Phe
                                               tgt ttg
        tct
              ttc
                                                           ttt
                                                                 gtt
                                                                      tgt
                                                                           ttg
                                                                                 ttc
                                                                                      Caa
                                               Cys Leu
       Ser
              Phe
                                                          Phe
                                                                Val
                                                                      Cys
                                                                          Lcu
                                                                                 Phc
                                                                                      Cln
  Lcu
                    1.0
                                                          ctg
                                                               CAG
                   gtc
                              ċсс
                                                     tca
                                                                      CCQ . AAt
                                                                                CLL
  tgt
        CCC
              888
                         CLC
                                    tgt
                                          CAC
                                               tca
                                                                                            389
                                                         -Leu Gln Pro
                                                                          Asn. ...<del>ib≐</del>u .:
                                   Cys
  Cys
        Pro
              Lys -Val
                        Lcu
                              Pro
                                         His
                                               Scr
                                                   Ser
               25
                                           30
                                                                                   × ...
 <210>
                2
                37
  <211>
  <212>
                PRT
               Paramecium sp.
  <213>
 <400>
                       Pho
                                                                     Cly Phq Cys
                                         Scr
                                              The Lys
                                                         rrp
                             Sċr
                                   Lcu
                                                    10
 Phe
             Cys
       Val
                       Pho
                                                               rro
                                                                    Cys
                  Lcu
                             Cln Cys
                                                   Va l
                                                         Leu
                                                                         His
                                                                               Scr
                                                                                     Ser
                   20
      Cln
            Pro
                  ۸sn
                       1.00
             15
 <210>
               3
<211>
              11
<212>
              ተጸተ
<213>
              Artificial Sequence
<220>
<223>
              Designed peptide based on size and polarity to act as a
              linker between the alpha and beta chains of Protein XYZ.
<400>
Het Val
            Λsn
                1.cu
                     Clu
                            tro Mcc His Thr Glu
                                                   10
<210>
<400>
000
```

[Annex VIII follows]

t

ತ

table. The numeric identifier shall be used only in the "Sequence Listing." The order and presentation of the items of information in the "Sequence Listing" shall conform to the arrangement given below. Each "Sequence Listing" shall conform to the arrangement given below. Each item of information shall begin on a new line and shall begin with the item of information shall begin on a new line and shall begin with the numeric identifier enclosed in angle brackets as shown. The submission of those items of information designated with an "M" is mandatory. The submission of those items of information designated with an "O" is submission of those items of information designated with an "O" is optional. Numeric identifiers <110> through <170> shall only be set forth at the beginning of the "Sequence Listing." The following table illustrates the numeric identifiers:

illustrates the numeric identities							
Numeric Identifier	Definition	Comments and Format	Mandatory (M) or Optional 10)				
<110>	Applicant	Preferably max. of 10 names; one name per line; preferable format: Surname, Other, Names and/or Initials	M v				
<120>	Title of Invention		B				
<130>	File Reference	Personal file reference	M, when filed prior to assignment of appl. number				
<140>	Current Applica- tion Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if available				
< 1 4 1 >	Current Filing Date	Specify as: yyyy-mm-dd	M, i(available				
<150>	Prior Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if applicable include priority documents under 35 USC 119 and 120				
<151>	Prior Application Filing Date	Specify as: yyyy-mm-dd	M, if applicable				
<160>	Number of SEQ 1D	Count includes total number of SEQ ID NOs	14				
<170>	Software	Name of software used to create the Sequence Listing	O				
<210>	SEQ ID NO: N:	Response shall be an integer representing the SEQ ID NO shown	м .				
<211>	Length	Respond with an integer expressing the number of bases or amino acid residues	M 				

... Whether presented sequence moleculc is DNA, RNA, or PRT (protein). If a nucleotide sequence contains both DNA and INA fragments, the type shall be "DNA." In addition, the combined DNA/ UNV wolccale shall be further described in the <220> to <223> [cature section.

<213> . Organism

Scientific name, i.e. Genus/species, Unknown or Artificial Sequence. In addition, the "Unknown" or "Artificial Sequence" organisms shall be further described in the <220> to <223> [eature section.

<220> Feature

Leave blank after (220). (221-223) provide for a description of points of biological significance in the sequence.

M, under the (ollowing conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGAN-ISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA.

<221> Name/Key

Provide appropriate identifier for feature, pre-ferably from WIPO Standard ST. 25 (1998).
Appendix 2, Tables 5 and 6

M, under the [ollowing conditions:=
i["n," "Xaa," or
a modified or unusual L-amino
acid or modified
base was used in
a sequence

<222> Location

Specify location within sequence; where appropriate state number of first and last bases/amino acids

M, under the following conditions:
if "n," "Xaa," or
a modified or unusual L-amino
acid or modified

1479799 1 53 PM

<300>	Publication Information	Leave blank ¹ after <300> /*	0 x \qquad t	ge ver
<301>	Authors	Preferably max of ten named authors of publi- cation; specify one name per line; preferable format: Surname, Other Names and/or Initials	· ·	
<302>	í Title		. 0	
<303>	Journal		0	·
< 304 >	Volume	· ·	0	
<305>	Issue	,	0	
<306>	Pages		Ο.	
<307>	Date	Journal date on which data published; specify as yyyy-mm-dd, MMM-yyyy or Season-yyyy	0	
< 300>	Database Accession Number	Accession number assigned by database including database name	0	
<309>	Database Entry	Date of entry in	0	

database; specify
as yyyy-mm-dd or
MMM-yyyy

Document number; O
for patent-type
citations only.
Specify as, for
example, US
07/999,999 -

t:

<310>

Date

Number

Patent Document

Document filing Patent Filing <311> date, for patent-Date type citations only; specify as yyyy-mm-dd o : Document publication. Publication Date <312> date, for patent-type citations only; specify as yyyy-mm-dd-<313> Relevant FROM (position) TO Residues (position) <400> SEQ ID NO should Sequence follow the numeric identifier and should appear on the line preceding the actual sequence

5. Section 1.024 is revised to read as follows:

- 1.024 Form and format for nucleotide and/or amino acid sequence submissions in computer readable form.
- (a) The computer readable (orm required by 1.021(c) shall meet the following specifications:
- (1) The computer readable form shall contain a single "Sequence Listing" as either a diskette, series of diskettes, or other permissible media: outlined in paragraph (c) of this section.
- (2) The "Sequence Listing" in paragraph (a) (1) of this section shall be submitted in American Standard Code for Information Interchange (ASCII) text. No other formats shall be allowed.
- (3) The computer readable form may be created by any means, such as word processors, nucleotide/amino acid sequence editors or other custom computer programs; however, it shall conform to all specifications detailed in this section.
- (4) File compression is acceptable when using diskette media, so long as the compressed file is in a self-extracting format that will decompress on one of the systems described in paragraph (b) of this section.
- (5) Page numbering shall not appear within the computer readable form version of the "Sequence Listing" (ile.
- (6) All computer readable forms shall have a label permanently affixed thereto on which has been hand-printed or typed: the name of the applicant, the title of the invention, the date on which the data were recorded on the computer readable form, the operating system used, a reference number, and an application serial number and filing date, if known.
- (b) Computer readable form submissions must meet these format requirements:
- (1) Computer: IBM PC/XT/AT, or compatibles, or Apple Macintosh;
- (2) Operating System: MS-DOS, Unix or Macintosh;

1/29.5/9 | 53 PM